ES2537096R1 - Inmunógenos de vih-1 deficientes en integrasa y métodos para cargar células dendríticas con dichos inmunógenos - Google Patents
Inmunógenos de vih-1 deficientes en integrasa y métodos para cargar células dendríticas con dichos inmunógenos Download PDFInfo
- Publication number
- ES2537096R1 ES2537096R1 ES201490077A ES201490077A ES2537096R1 ES 2537096 R1 ES2537096 R1 ES 2537096R1 ES 201490077 A ES201490077 A ES 201490077A ES 201490077 A ES201490077 A ES 201490077A ES 2537096 R1 ES2537096 R1 ES 2537096R1
- Authority
- ES
- Spain
- Prior art keywords
- immunogens
- hiv
- dendritic cell
- methods
- deficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000002950 deficient Effects 0.000 title abstract 2
- 210000004443 dendritic cell Anatomy 0.000 abstract 5
- 102100034343 Integrase Human genes 0.000 abstract 2
- 108010061833 Integrases Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000004041 dendritic cell maturation Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Inmunógenos de VIH-1 deficientes en integrasa y métodos para cargar células dendríticas con dichos inmunógenos.#La presente invención se refiere a un método para obtener una célula dendrítica cargada con antígeno in vitro que comprende poner en contacto una célula dendrítica inmadura con un inmunógeno, preferiblemente un inmunógeno de VIH, y simultáneamente, durante al menos parte de dicho paso, colocar dicha célula dendrítica inmadura en condiciones adecuadas para la maduración que comprenden la incubación de dicha célula dendrítica con un medio que comprende un agente de maduración de células dendríticas seleccionado entre el ligando de TLR4 LPS, y una mezcla de citocinas proinflamatorias seleccionadas entre IL-1{be}, IL-6 y TNF-{al}, y la prostaglandina PGE{sub,2}. La invención se refiere también a inmunógenos de VIH-1 que carecen de una proteína integrasa funcional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12382016.9A EP2617434A1 (en) | 2012-01-20 | 2012-01-20 | HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
EP12382016 | 2012-01-20 | ||
PCT/EP2013/050929 WO2013107854A1 (en) | 2012-01-20 | 2013-01-18 | Hiv-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
Publications (3)
Publication Number | Publication Date |
---|---|
ES2537096A2 ES2537096A2 (es) | 2015-06-02 |
ES2537096R1 true ES2537096R1 (es) | 2015-08-13 |
ES2537096B1 ES2537096B1 (es) | 2016-05-24 |
Family
ID=47594746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201490077A Active ES2537096B1 (es) | 2012-01-20 | 2013-01-18 | Inmunogenos de vih-1 deficientes en integrasa y metodos para cargar celulas dendriticas con dichos inmunogenos |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2617434A1 (es) |
ES (1) | ES2537096B1 (es) |
WO (1) | WO2013107854A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3018819A1 (fr) * | 2014-03-19 | 2015-09-25 | Univ Bourgogne | Traitement de la reponse inflammatoire et dysimmunitaire |
CN103948917A (zh) * | 2014-04-02 | 2014-07-30 | 江苏和泽生物科技有限公司 | 树突状细胞疫苗的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007098326A2 (en) * | 2006-02-10 | 2007-08-30 | Case Western Reserve University | Method for screening hiv drug sensitivity |
WO2007110240A1 (en) * | 2006-03-28 | 2007-10-04 | Helmholtz Zentrum München - Deutsches Forschungszentrum Für Umwelt Und Gesundheit Gmbh | Compositions for the preparation of mature dendritic cells |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
US6835393B2 (en) | 1998-01-05 | 2004-12-28 | University Of Washington | Enhanced transport using membrane disruptive agents |
WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
-
2012
- 2012-01-20 EP EP12382016.9A patent/EP2617434A1/en not_active Withdrawn
-
2013
- 2013-01-18 ES ES201490077A patent/ES2537096B1/es active Active
- 2013-01-18 WO PCT/EP2013/050929 patent/WO2013107854A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007098326A2 (en) * | 2006-02-10 | 2007-08-30 | Case Western Reserve University | Method for screening hiv drug sensitivity |
WO2007110240A1 (en) * | 2006-03-28 | 2007-10-04 | Helmholtz Zentrum München - Deutsches Forschungszentrum Für Umwelt Und Gesundheit Gmbh | Compositions for the preparation of mature dendritic cells |
Non-Patent Citations (8)
Title |
---|
AHLERS, J. D. et al. Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.Trends in Molecular Medicine. Junio 2009, Vol. 15, Nº 6, páginas: 263 - 274. ISSN 1471-4914 <Doi:10.1016/j.molmed.2009.04.003> * |
BUKOVSKY, A. et al. Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease. Journal of Virology. Octubre 1996, Vol. 70, Nº 10, páginas: 6820 - 6825. ISSN 0022-538X * |
IZQUIERDO-USEROS, N. et al. Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission. Journal of Virology. Julio 2007, Vol. 81, Nº 14, páginas: 7559 - 7570. ISSN 0022-538X <Doi:10.1128/JVI.02572-06> * |
LANDI, A. et al. Dendritic cells matured by a prostaglandin E2-containing cocktail can produce high levels of IL-12p70 and are more mature and Th1-biased than dendritic cells treated with TNF-[alpha] or LPS. Immunobiology. Junio 2011, Vol. 216, Nº 6, páginas: 649 - 662. ISSN 0171-2985 <Doi:10.1016/j.imbio.2010.11.004>LANDI, A. et al. Dendritic cells matured by a prostaglandin E2-containing cocktail can produce high levels of IL-12p70 and are more mature and Th1-biased than dendritic cells treated with TNF-[alpha] or LPS. Immunobiology. Junio 2011, Vol. 216, Nº 6, páginas: 649 - 662. ISSN 0171-2985 <Doi:10.1016/j.imbio.2010.11.004> * |
RODRIGUEZ-PLATA, M. T et al. HIV-1 Capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T cell activation. Journal of Immunology. Junio 2012, Vol. 188, Nº 12, páginas: 6036-6045. ISSN 0022-1767 <Doi:10.4049/jimmunol.1200267> * |
ROSSOWSKA, J. et al. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo. Oncology Reports. Junio 2009, Vol. 21, Nº 6, páginas: 1539-1549. ISSN 1021-335X. <Doi:10.3892/or_00000386>ROSSOWSKA, J. et al. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo. Oncology Reports. Junio 2009, Vol. 21, Nº 6, páginas: 1539-1549. ISSN 1021-335X. <Doi:10.3892/or_00000386> * |
THUMANN, P. et al. Antigen loading of dendritic cells with whole tumor cell preparations. Journal of Immunological Methods. Junio 2003, Vol. 277, Nº 1-2, páginas: 1 - 16. ISSN 0022-1759. <Doi:10.1016/S0022-1759(03)00102-9>THUMANN, P. et al. Antigen loading of dendritic cells with whole tumor cell preparations. Journal of Immunological Methods. Junio 2003, Vol. 277, Nº 1-2, páginas: 1 - 16. ISSN 0022-1759. <Doi:10.1016/S0022-1759(03)00102-9> * |
VAN GULCK, E .R. A. et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood. Marzo 2006, Vol. 107, Nº 5, páginas: 1818 - 1827. ISSN 0006-4971. <Doi:10.1182/blood-2005-01-0339> * |
Also Published As
Publication number | Publication date |
---|---|
ES2537096B1 (es) | 2016-05-24 |
EP2617434A1 (en) | 2013-07-24 |
WO2013107854A1 (en) | 2013-07-25 |
ES2537096A2 (es) | 2015-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014502381A1 (en) | High oleic acid oils | |
AR081558A1 (es) | Extraccion de lipidos de celulas y productos provenientes de ellos | |
EP2469226A3 (de) | Optisches System zur Strahlformung eines Laserstrahls sowie Lasersystem mit einem solchen optischen System | |
MX2016016251A (es) | Expansion de linfocitos con composicion de citocinas para inmunoterapia celular activa. | |
GB201210134D0 (en) | Selective sidewall growth of semiconductor material | |
AR094464A1 (es) | PRODUCCIÓN DE ÁCIDOS w-AMINO GRASOS | |
GB2466983B (en) | A method and apparatus for supporting a load | |
MX337634B (es) | Anillos intravaginales monoliticos que comprenden progesterona y metodos de manufactura y uso de los mismos. | |
IN2014DE01724A (es) | ||
PH12017500015A1 (en) | Aerated confection with interfacially stabilised air cells | |
AR067084A1 (es) | Dispersion solida que contiene revaprazan y procedimiento para la preparacion de la misma. composicion farmaceutica. | |
WO2014122035A3 (en) | Induced dendritic cells and uses thereof | |
ES2537096R1 (es) | Inmunógenos de vih-1 deficientes en integrasa y métodos para cargar células dendríticas con dichos inmunógenos | |
SG11201805846TA (en) | Method for producing hepatic stem/precursor cells from mature hepatic cells using low-molecular-weight compound | |
PE20190517A1 (es) | Preparacion farmaceutica antienvejecimiento | |
TWD171963S (zh) | 晶圓舟之晶圓支撐爪(一) | |
AR068580A1 (es) | Procedimiento para extraer teaflavinas del te | |
WO2012069691A8 (en) | Arrangement and method for testing the load-supporting capability of a lifting fixture | |
GB2565951A (en) | Hoisting system | |
WO2012110289A3 (en) | Test and inspection arrangement for subsea well equipment | |
TWD175115S (zh) | 晶圓舟之晶圓支撐爪(二) | |
EP4273232A3 (en) | B-cell cultivation method | |
GB201202746D0 (en) | Transaction-level interoperability over a tactical data link | |
ES2689084T3 (es) | Método de diagnóstico de la galactosemia en un cribado neonatal | |
ATE508640T1 (de) | Waffelgrundkörper, zugehörige waffelform und produktionsmethode |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2537096 Country of ref document: ES Kind code of ref document: B1 Effective date: 20160524 |